Authors: Martha Powell, Future Science Group
A pioneering treatment, developed by researchers at the Medical Research Council (MRC) Prion Unit at University College London (UK), is to be given to a patient with Creutzfeldt-Jakob disease (CJD) for the first time.
CJD currently has no treatment; it is always fatal and most patients have a rapid decline, with mortalities often occurring just 6 weeks after diagnosis.
Restricted Content / Members Only
